HIV incidence determination in the United States: a multiassay approach

J Infect Dis. 2013 Jan 15;207(2):232-9. doi: 10.1093/infdis/jis659. Epub 2012 Nov 5.

Abstract

Background: Accurate testing algorithms are needed for estimating human immunodeficiency virus (HIV) incidence from cross-sectional surveys.

Methods: We developed a multiassay algorithm (MAA) for HIV incidence that includes the BED capture enzyme immunoassay (BED-CEIA), an antibody avidity assay, HIV load, and CD4(+) T-cell count. We analyzed 1782 samples from 709 individuals in the United States who had a known duration of HIV infection (range, 0 to >8 years). Logistic regression with cubic splines was used to compare the performance of the MAA to the BED-CEIA and to determine the window period of the MAA. We compared the annual incidence estimated with the MAA to the annual incidence based on HIV seroconversion in a longitudinal cohort.

Results: The MAA had a window period of 141 days (95% confidence interval [CI], 94-150) and a very low false-recent misclassification rate (only 0.4% of 1474 samples from subjects infected for >1 year were misclassified as indicative of recent infection). In a cohort study, annual incidence based on HIV seroconversion was 1.04% (95% CI, .70%-1.55%). The incidence estimate obtained using the MAA was essentially identical: 0.97% (95% CI, .51%-1.71%).

Conclusions: The MAA is as sensitive for detecting recent HIV infection as the BED-CEIA and has a very low rate of false-recent misclassification. It provides a powerful tool for cross-sectional HIV incidence determination.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Algorithms
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • HIV Antibodies / blood
  • HIV Antibodies / physiology
  • HIV Infections / diagnosis*
  • HIV Infections / epidemiology*
  • HIV Infections / immunology
  • HIV Seropositivity / epidemiology
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • Humans
  • Immunoenzyme Techniques
  • Incidence
  • Male
  • Viral Load

Substances

  • HIV Antibodies